Newsletter

FDA Accepts Jazz Pharmaceuticals’ NDA for Solriamfetol Treatment in Patients with Narcolepsy and Sleep Apnea

On March 2, Jazz Pharmaceuticals plc (JAZZ) announced that the FDA has accepted the company’s filing of a New Drug Application (NDA) with standard review for market approval of Solriamfetol. The drug is an investigational medicine used for the treatment of excessive sleepiness in patients with narcolepsy and obstructive sleep apnea (OSA). The company hopes […]

0Comments

February 2018 Scorecard

The February 2018 scorecard for the signals generated from Rocket Tickers can be downloaded here. For more information regarding how you can trade these signals, see the article Trading Clinical Trials Try Rocket Tickers 30 days for free and cancel anytime! Subscribe here and check out the Training Webinar Remember to enter the promo code: […]

0Comments

Sorrento Therapeutics Subsidiary Receives FDA Approval for Non-Opiod Ztlido

On February 28, Sorrento Therapeutics (SRNE) Subsidiary, Scilex, received FDA approval for non-opiod Ztlido. The drug is a lidocaine topical system used to treat pain. Sorrento hopes to have it commercially available to patients later this year.   Rocket Tickers received the news and sent an alert to subscribers at 2:11 pm. The next trade […]

0Comments

June 2018 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: December 2017 Scorecard Number of Signals 24 Percent Correct – Prev Close to 5-day Peak 100% Avg Increase – Next Close to 5-day Peak 4% Other stats: Number of signals over $10/share 16 […]

0Comments

Qiagen Receives FDA Approval to Expand Use of EGFR Test for Lung Cancer

Qiagen N.V. (QGEN) announced on January 18 that the company received FDA approval to extend the use of its EGFR test for lung cancer. Qiagen’s therascreen EGFR test is used in conjunction with the targeted therapy GILOTRIF as a first-line treatment for metastatic small cell lung cancer. The FDA approval extends the labeling of the […]

0Comments

Myriad Genetics Receives FDA Approval for Breast Cancer Diagnostic Test

On January 12, Myriad Genetics, Inc. (MYGN) announced that the FDA has approved BRACAnalysis CDx as a companion diagnostic for metastatic breast cancer. Healthcare professionals will be able to use this to identify patients with HER2-negative metastatic breast cancer who have a BRCA mutation and may be candidates for treatment with the PARP inhibitor, Lynparza. […]

0Comments

December 2017 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: December 2017 Scorecard Number of Signals 17 Percent Correct – Prev Close to 5-day Peak 88% Avg Increase – Next Close to 5-day Peak 7% Other stats: Number of signals over $10/share 11 […]

0Comments

La Jolla Pharmaceutical Announces FDA Approval of Giapreza

On December 21, La Jolla Pharmaceutical Company (LJPC) announced that the FDA approved its drug, Giapreza (angiotensin II). The drug can be used to increase blood pressure in adult patients suffering from septic shock or other distributive shock. La Jolla expects to have the drug available for patients in March 2018. Rocket Tickers detected the […]

0Comments

Exelixis Receives FDA Approval for Cabometyx to Treat Renal Cell Carcinoma

On December 19, Exelixis, Inc. (EXEL) announced that the company received additional FDA approval for its drug, Cabometyx. The drug received a label expansion so that it can be used to treat previously untreated advanced renal cell carcinoma. Cabometyx already experienced strong sales in the first nine months of 2017 due to strong demand for […]

0Comments

November 2017 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: November 2017 Scorecard Number of Signals 21 Percent Correct – Next Close to 5-day Peak 85.7% Avg Increase – Next Close to 5-day Peak 9.3% Other stats: Number of signals over $10/share 13 […]

0Comments